Efficacy and safety of mycophenolate mofetil for lichen planopilaris.
J Am Acad Dermatol
; 62(3): 393-7, 2010 Mar.
Article
en En
| MEDLINE
| ID: mdl-20061053
ABSTRACT
BACKGROUND:
Lichen planopilaris (LPP) is a chronic inflammatory disorder that causes permanent scalp hair loss and significant patient discomfort.OBJECTIVES:
We sought to determine the efficacy and safety of mycophenolate mofetil (MMF) for treatment of LPP in patients who had failed prior topical, intralesional, or oral anti-inflammatory medications such as hydroxychloroquine or cyclosporine.METHODS:
We conducted a retrospective chart review of 16 adult patients with LPP treated with at least 6 months of MMF in an open-label, single-center study from 2003 to 2007. Subjective and objective end points were quantified using the LPP Activity Index (LPPAI) and scores before and after treatment were assessed using a paired t test. Adverse events were monitored.RESULTS:
Patients who completed treatment with MMF had significantly decreased signs and symptoms of active LPP despite having failed multiple prior therapies (P < .005). Five of 12 patients were complete responders (LPPAI score decreased>85%), 5 of 12 patients were partial responders (LPPAI score decreased 25%-85%), and two of 12 patients were treatment failures (LPPAI score decreased<25%). Four patients withdrew from the trial because of adverse events.LIMITATIONS:
Retrospective analysis and small sample size were limitations.CONCLUSIONS:
MMF was effective at reducing the signs and symptoms of active LPP in 83% of patients (10 of 12) who had failed multiple prior treatments after at least 6 months of treatment.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Dermatosis del Cuero Cabelludo
/
Alopecia
/
Liquen Plano
/
Ácido Micofenólico
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
2010
Tipo del documento:
Article
País de afiliación:
Estados Unidos